S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Sympathoadrenal Stress Reactivity Is a Predictor of Future Blood Pressure: An 18-Year Follow-Up Study
TL;DR: It is shown that sympathetic nervous activity during mental arithmetic predicts future blood pressure, indicating a possible causal factor in the development of essential hypertension independent of the initial blood pressure.
Journal ArticleDOI
Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.
Felix Mahfoud,Michael Böhm,Michel Azizi,Atul Pathak,Isabelle Durand Zaleski,Sebastian Ewen,Kostantinos Tsioufis,Bert Andersson,Peter J. Blankestijn,Michel Burnier,Gilles Chatellier,Sameer Gafoor,Guido Grassi,Michael Joner,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Thomas F. Lüscher,Melvin D. Lobo,Chaim Lotan,Gianfranco Parati,Josep Redon,Luis M. Ruilope,Isabella Sudano,Christian Ukena,Evert van Leeuwen,Massimo Volpe,Stephan Windecker,Adam Witkowski,William Wijns,Thomas Zeller,Roland E. Schmieder +30 more
TL;DR: Clinical evidence in support of RDN as an effective interventional technique in patients with resistant hypertension is conflicting; a number of observational studies and three randomized, controlled trials support both safety and efficacy of this new therapy but some smaller studies and the large, single-blind, randomized, sham-controlled symplicity HTN-3 trial failed to show superiority ofRDN when compared with medical therapy alone.
Journal ArticleDOI
H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study
Björn Dahlöf,Richard D. Devereux,U. DeFaire,Frej Fyhrquist,Thomas Hedner,H. Ibsen,S. Julius,Sverre E. Kjeldsen,Krister Kristianson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
Journal ArticleDOI
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study
Alberto Zanchetti,Lennart Hansson,Björn Dahlöf,Dag Elmfeldt,Sverre E. Kjeldsen,R. Kolloch,Pierre Larochelle,Gordon T. McInnes,Jean Michel Mallion,Luis M. Ruilope,Hans Wedel +10 more
TL;DR: The findings emphasize the importance of addressing other correctable risk factors, e.g. smoking, hypercholesterolaemia and diabetes, as well as rigorous control of blood pressure, and of initiating antihypertensive therapy before cardiovascular and renal damage becomes manifest.
Journal ArticleDOI
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
Kristian Wachtell,Michael H. Olsen,Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Markku S. Nieminen,Peter M. Okin,Vasilios Papademetriou,Carl Erik Mogensen,Knut Borch-Johnsen,Hans Ibsen +10 more
TL;DR: In patients with moderately severe hypertension, left ventricular hypertrophy on two consecutive ECGs is associated with increased prevalences of micro- and macroalbuminuria compared to patients without persistent ECGs, suggesting parallel cardiac damage and albuminuria.